We are pleased to announce GlyTherix is presenting an e-poster titled “Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab.” This will showcase our groundbreaking research in the field of dosimetry and radiobiology.
📅 Dates: October 19-23, 2024.
📍 Location: Hamburg, Germany.
🔖 Session Title: D: Technical Studies -> D4 Dosimetry and Radiobiology -> D42 Clinical Dosimetry.
📌 e-Poster Number: EP-0916 🕒 Session Number: EP-58.
We look forward to sharing our findings and discussing the potential impact on enhancing diagnostic and therapeutic precision in cancer treatment at EANM.